PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

As regards Pfizer, oncology sales ... of Pfizer’s diversified portfolio of drugs, particularly oncology, ... currently trade at 8.24 forward earnings, higher than 7.41 for Pfizer.

Estimates for Vertex Pharmaceuticals’ 2022 earnings have gone up from $14.52 to $14.56 per share, while those for 2023 have increased from $15.31 to $15.35 per share over the past 30 days.

Oncology’s Contribution To Pfizer’s EPS. We use adjusted net income margin of around 32%, similar to that of Pfizer overall, to arrive at $0.36 contribution to Pfizer’s total earnings.

The New York-based drug company (PFE) had net income of $4.465 billion, or 78 cents a share, for the quarter, after a loss of $2.382 billion, or 42 cents a share, in the year-earlier period.

Pfizer Chief Executive Albert Bourla is feeling more confident in his $43 billion acquisition of Seagen – thanks to the buzz around antibody-drug conjugate cancer drugs. “I feel way more ...

Pfizer’s PFE Biopharmaceuticals Group, which comprises six business units — Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine — is expected to have ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...